Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

M 011

Next Previous
Drug Profile

M 011

Alternative Names: GBAM6P; M-011

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator M6P Therapeutics
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gaucher's disease

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for preclinical development in Gaucher's-disease in USA
  • 09 Feb 2023 M6P Therapeutics plans to submit IND in Gaucher's disease by Q1 2023 (M6P Therapeutics website, February 2023)
  • 10 Feb 2022 Pharmacodynamics data from preclinical trial presented at the 18th Annual WORLDSymposium™ (Annual WORLDSymposium-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top